128537-26-8 Usage
Uses
Used in Pharmaceutical Industry:
3-ETHYL-1-METHYL-1H-PYRAZOLE-5-CARBOXYLIC ACID ETHYL ESTER serves as a crucial intermediate in the synthesis of new drugs, contributing to the advancement of medicinal chemistry. Its unique structure allows for the development of compounds with potential therapeutic applications.
Used in Agrochemicals:
In the agrochemical sector, 3-ETHYL-1-METHYL-1H-PYRAZOLE-5-CARBOXYLIC ACID ETHYL ESTER is utilized for its potential to enhance crop protection and management strategies, thereby improving agricultural productivity.
Used in Organic Synthesis:
3-ETHYL-1-METHYL-1H-PYRAZOLE-5-CARBOXYLIC ACID ETHYL ESTER is employed as a building block in the synthesis of a variety of organic compounds, showcasing its versatility and importance in chemical research and development.
Used in Anti-inflammatory and Analgesic Research:
3-ETHYL-1-METHYL-1H-PYRAZOLE-5-CARBOXYLIC ACID ETHYL ESTER has been studied for its potential anti-inflammatory and analgesic properties, indicating its possible use in the development of treatments for pain and inflammation-related conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 128537-26-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,8,5,3 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 128537-26:
(8*1)+(7*2)+(6*8)+(5*5)+(4*3)+(3*7)+(2*2)+(1*6)=138
138 % 10 = 8
So 128537-26-8 is a valid CAS Registry Number.
128537-26-8Relevant articles and documents
Synthesis of fluorinated and nonfluorinated tebufenpyrad analogues for the study of anti-angiogenesis MOA
Roman, Raquel,Navarro, Antonio,Wodka, Dariusz,Alvim-Gaston, Maria,Husain, Saba,Franklin, Natalie,Simon-Fuentes, Antonio,Fustero, Santos
, p. 1027 - 1036 (2014/10/15)
In this contribution we report the synthesis of fluorinated and nonfluorinated tebufenpyrad analogues to explore potential druglike properties through the phenotypic screening as part of the Lilly Open Innovation Drug Discovery (OIDD) program.